John Stagg
Centre Hospitalier de l’Université de Montréal · 265 works · 19,537 citations · h-index 56
Top works
- Anti–ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti–PD-1 or anti-CD137 mAb therapy
- Immune evasion in cancer: Mechanistic basis and therapeutic strategies
- Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy
- Consensus guidelines for the detection of immunogenic cell death
- Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis
- Consensus guidelines for the definition, detection and interpretation of immunogenic cell death
- Allogeneic marrow stromal cells are immune rejected by MHC class I– and class II–mismatched recipient mice
- Extracellular adenosine triphosphate and adenosine in cancer
- CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer
- The ectonucleotidases CD 39 and CD 73: Novel checkpoint inhibitor targets
- CD73-Deficient Mice Have Increased Antitumor Immunity and Are Resistant to Experimental Metastasis
- Targeting CD73 Enhances the Antitumor Activity of Anti-PD-1 and Anti-CTLA-4 mAbs
- Interferon-γ-stimulated marrow stromal cells: a new type of nonhematopoietic antigen-presenting cell
- Blockade of A 2A receptors potently suppresses the metastasis of CD73 + tumors
- CD73: a potent suppressor of antitumor immune responses
- Targeting Cancer-Derived Adenosine:New Therapeutic Approaches
- The adenosine pathway in immuno-oncology
- CD73-Deficient Mice Are Resistant to Carcinogenesis
- Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death
- Spatially distinct tumor immune microenvironments stratify triple-negative breast cancers